CD69 and COVID-19: Indeed, when we compared the phenotype of ILC2 present in the PBMC of HC and COVID-19 patients, we found that COVID-19 patients’ ILC2 showed a more activated phenotype characterized by an increase in CD38 and CD69 expression and a trend for increased NKG2D (Figure 7C).